Chapel Hill, North Carolina 27599


Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressing lung disease caused by a number of factors including pneumonia, sepsis and acute trauma that leads to reduced lung function and breathlessness. There are no pharmacological treatments approved for the treatment of ARDS. This pilot trial will study the safety and efficacy of Treprostinil sodium by inhalation for preventing the progression of acute hypoxemic respiratory failure to positive pressure ventilation and/or ARDS in patients at high risk.

Study summary:

ARDS is defined by acute hypoxemia, respiratory failure and the presence of bilateral lung infiltrates. ARDS is a syndrome of inflammation and increased permeability that may coexist with left atrial or pulmonary capillary hypertension. Several recent trials in ARDS/ALI (Acute Lung Injury) have generated interest in the use of Prostacyclin (PGI2) and prostacyclin analogs in improving oxygenation in ARDS/ALI. PGI2 is an arachidonic acid metabolite naturally produced in the lung by endothelial cells, dendritic cells, smooth muscle cells and fibroblasts. PGI2 is a potent selective pulmonary vasodilator and inhibitor of platelet aggregation. The cellular effects include smooth muscle relaxation, inhibition of cell migration, decreased dextran permeability in epithelial cell cultures in vitro, decreased high tidal volume mechanical ventilation injury in mice and inhibition of fibroblast adhesion and differentiation. PGI2 has broad anti-inflammatory activity, inhibiting the production of Tumor necrosis factor alpha (TNFα), interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and granulocyte macrophage colony-stimulating factor (GMCSF) in human alveolar macrophages. The study objectives are: 1. To assess the feasibility of a randomized trial of treprostinil inhalation in patients with acute hypoxemic respiratory failure not requiring positive pressure ventilation. 2. To evaluate the tolerability of inhaled treprostinil for patients with acute hypoxemic respiratory failure 3. To assess the effect of treprostinil inhalation on oxygenation in patients with acute hypoxic respiratory failure with, or at risk for, development of ARDS 4. To assess the effect of treprostinil inhalation on various biomarkers thought to be related to the pathogenesis and/or clinical course of ARDS. The hypothesis is: Treprostinil solution for inhalation (TYVASO) is safe and will improve oxygenation and other secondary outcomes related to acute hypoxemic respiratory failure and positive pressure ventilation initiation and duration, as well as exhibit effects on ARDS-related pro-inflammatory and pro-fibrotic biomarkers.


Inclusion Criteria: 1. Adults age 18-75 years. 2. Acute onset need for 4 liters per minute (LPM) or more of supplemental oxygen to maintain PaO2 > 60 mmHg or arterial O2 saturation > 90% by pulse oximetry. 3. Acute unilateral pulmonary infiltrate/s on chest radiograph with no clinical evidence of left-sided heart failure. Bilateral infiltrates are acceptable as long as all other inclusion/exclusion criteria are met. Exclusion Criteria: 1. No consent/inability to obtain consent 2. Presence of pulmonary embolism 3. Known diffuse alveolar hemorrhage from vasculitis 4. Known pre-existing severe obstructive or restrictive lung disease (FEV 1 < 40% predicted, total lung capacity (TLC) < 50 % predicted) or need for long-term supplemental oxygen therapy 5. Known significant left ventricular systolic dysfunction with left ventricular ejection fraction (LVEF) < 45% on echocardiogram. 6. Mean arterial pressure < 65 mmHg 7. Need for norepinephrine or dopamine dose > 12 mcg to maintain MAP > 65 mmHg 8. Severe chronic liver disease (Child-Pugh Score 11-15) 9. Moribund patient not expected to survive 24 hours 10. Corrected QT interval (QTc) interval > 500 ms on screening electrocardiogram 11. Pregnancy or breast feeding (Women of childbearing potential, defined as < 60 years of age, will require pregnancy testing.) 12. Burns > 40% total body surface 13. Acute Neurological Disease (that may impair the ability to ventilate without assistance) 14. Imminent need for intubation or non-invasive ventilation 15. Patient is Do Not Resuscitate/Do Not Intubate 16. Patient has a tracheotomy 17. Patient is currently receiving prostacyclin therapy [Epoprostenol (Flolan or Veltri), Iloprost (Ventavis), Treprostinil (Orenitram, oral) (Remodulin, IV or SC)] 18. Patient has a language barrier



Primary Contact:

Principal Investigator
Hubert J Ford, MD
University of North Carolina, Chapel Hill

Hubert J Ford, MD
Phone: 919 966-2531

Backup Contact:

Joyce Lanier, RRT
Phone: 966-2531

Location Contact:

Chapel Hill, North Carolina 27599
United States

James Ford, MD
Phone: 919-966-2531

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.